ATE322264T1 - Medizinische zusammensetzungen als begleittherapie gegen krebs - Google Patents

Medizinische zusammensetzungen als begleittherapie gegen krebs

Info

Publication number: ATE322264T1
Authority: AT; Austria
Prior art keywords: ring; salt; substituent group; companionary; against cancer
Prior art date: 2000-10-31

Application number

AT01978983T

Other languages

English (en)

Inventor

Yoichi Ozawa

Kentaro Yoshimatsu

Junko Kai

Original Assignee

Eisai Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-31

Filing date

2001-10-31

Publication date

2006-04-15

2001-10-31 Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd

2006-04-15 Application granted granted Critical

2006-04-15 Publication of ATE322264T1 publication Critical patent/ATE322264T1/de

Links

239000000203 mixture Substances 0.000 title abstract 3
206010028980 Neoplasm Diseases 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
238000002560 therapeutic procedure Methods 0.000 title 1
150000003839 salts Chemical class 0.000 abstract 3
125000001424 substituent group Chemical group 0.000 abstract 3
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 abstract 2
125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
-1 sulfonamide compound Chemical class 0.000 abstract 2
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 abstract 1
229930012538 Paclitaxel Natural products 0.000 abstract 1
230000000259 anti-tumor effect Effects 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
229910052799 carbon Inorganic materials 0.000 abstract 1
125000004432 carbon atom Chemical group C* 0.000 abstract 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
229960004316 cisplatin Drugs 0.000 abstract 1
229960004679 doxorubicin Drugs 0.000 abstract 1
229960002949 fluorouracil Drugs 0.000 abstract 1
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 abstract 1
229960005144 gemcitabine hydrochloride Drugs 0.000 abstract 1
125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
SETFNECMODOHTO-UHFFFAOYSA-N indisulam Chemical compound C1=CC(S(=O)(=O)N)=CC=C1S(=O)(=O)NC1=CC=CC2=C1NC=C2Cl SETFNECMODOHTO-UHFFFAOYSA-N 0.000 abstract 1
229950010538 irinotecan hydrochloride trihydrate Drugs 0.000 abstract 1
229960004857 mitomycin Drugs 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
229960001592 paclitaxel Drugs 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
229940124530 sulfonamide Drugs 0.000 abstract 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
229930195735 unsaturated hydrocarbon Natural products 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT01978983T 2000-10-31 2001-10-31 Medizinische zusammensetzungen als begleittherapie gegen krebs ATE322264T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2000333952		2000-10-31

Publications (1)

Publication Number	Publication Date
ATE322264T1 true ATE322264T1 (de)	2006-04-15

Family

ID=18809950

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01978983T ATE322264T1 (de)	2000-10-31	2001-10-31	Medizinische zusammensetzungen als begleittherapie gegen krebs

Country Status (12)

Country	Link
US (3)	US20040002505A1 (de)
EP (1)	EP1331005B1 (de)
JP (1)	JP4167898B2 (de)
KR (1)	KR100829875B1 (de)
CN (1)	CN1196484C (de)
AT (1)	ATE322264T1 (de)
AU (2)	AU1099302A (de)
CA (1)	CA2427617C (de)
DE (1)	DE60118590T2 (de)
NZ (1)	NZ524975A (de)
TW (1)	TWI283575B (de)
WO (1)	WO2002036117A1 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU9598601A (en)	2000-10-20	2002-04-29	Eisai Co Ltd	Nitrogenous aromatic ring compounds
ATE508747T1 (de) *	2003-03-10	2011-05-15	Eisai R&D Man Co Ltd	C-kit kinase-hemmer
DE602004010900D1 (de) *	2003-05-08	2008-02-07	Eisai R&D Man Co Ltd	Medizinische zusammensetzungen enthaltend n-(3-chloro-1h-indol-7-yl)-4-sulfamoylbenzensulfonamid und weitere cytostatika
WO2005026118A1 (ja) *	2003-09-10	2005-03-24	Eisai Co., Ltd.	スルホンアミド含有インドール化合物の結晶およびその製造方法
WO2005026119A1 (ja) *	2003-09-10	2005-03-24	Eisai Co., Ltd.	スルホンアミド含有インドール化合物の製造方法
US7683172B2 (en)	2003-11-11	2010-03-23	Eisai R&D Management Co., Ltd.	Urea derivative and process for preparing the same
AU2004312530A1 (en) *	2003-12-29	2005-07-21	Sepracor Inc.	Pyrrole and pyrazole DAAO inhibitors
JP2007525507A (ja) *	2004-02-26	2007-09-06	ザペンステイトリサーチファンデーション	オピオイド増殖因子レセプターを用いる、新生物の処置のための組み合わせ療法
ATE428421T1 (de)	2004-09-17	2009-05-15	Eisai R&D Man Co Ltd	Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
JP5106098B2 (ja) *	2005-02-28	2012-12-26	エーザイ・アール・アンド・ディー・マネジメント株式会社	スルホンアミド化合物の抗癌剤との新規併用
CN1313104C (zh) *	2005-05-27	2007-05-02	中国科学院南海海洋研究所	一种具有柴胡和多霉素协同作用的抗癌药物组合物
JP2009500425A (ja)	2005-07-06	2009-01-08	セプラコアインコーポレーテッド	エスゾピクロン及びトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−ｎ−メチル−１−ナフタレンアミン又はトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法
WO2007015569A1 (ja) *	2005-08-01	2007-02-08	Eisai R & D Management Co., Ltd.	血管新生阻害物質の効果を予測する方法
JP4989476B2 (ja)	2005-08-02	2012-08-01	エーザイ・アール・アンド・ディー・マネジメント株式会社	血管新生阻害物質の効果を検定する方法
CA2620594C (en) *	2005-09-01	2012-08-21	Eisai R&D Management Co., Ltd.	Pharmaceutical composition having improved disintegratability
AU2006309551B2 (en)	2005-11-07	2012-04-19	Eisai R & D Management Co., Ltd.	Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
EP1964837A4 (de) *	2005-11-22	2010-12-22	Eisai R&D Man Co Ltd	Antitumormittel gegen multiples myelom
NZ569608A (en) *	2006-01-06	2011-09-30	Sepracor Inc	Tetralone-based monoamine reuptake inhibitors
BRPI0706365A2 (pt)	2006-01-06	2011-03-22	Sepracor Inc	Cicloalquilaminas como inibidores da recaptação de monoamina
DK2816024T3 (en)	2006-03-31	2017-10-30	Sunovion Pharmaceuticals Inc	CHIRALE AMINER
CN104706637A (zh) *	2006-05-18	2015-06-17	卫材R&D管理有限公司	针对甲状腺癌的抗肿瘤剂
JPWO2008001956A1 (ja) *	2006-06-29	2009-12-03	エーザイ・アール・アンド・ディー・マネジメント株式会社	肝線維症治療剤
US7579370B2 (en) *	2006-06-30	2009-08-25	Sepracor Inc.	Fused heterocycles
US7884124B2 (en) *	2006-06-30	2011-02-08	Sepracor Inc.	Fluoro-substituted inhibitors of D-amino acid oxidase
US20080058395A1 (en) *	2006-06-30	2008-03-06	Sepracor Inc.	Fused heterocyclic inhibitors of D-amino acid oxidase
WO2008026748A1 (en)	2006-08-28	2008-03-06	Eisai R & D Management Co., Ltd.	Antitumor agent for undifferentiated gastric cancer
US7902252B2 (en) *	2007-01-18	2011-03-08	Sepracor, Inc.	Inhibitors of D-amino acid oxidase
US20090099248A1 (en) *	2007-01-18	2009-04-16	Sepracor Inc.	Inhibitors of d-amino acid oxidase
CA2676796C (en)	2007-01-29	2016-02-23	Eisai R & D Management Co., Ltd.	Composition for treatment of undifferentiated gastric cancer
AU2008259841B2 (en)	2007-05-31	2015-02-05	Sunovion Pharmaceuticals Inc.	Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
US8952035B2 (en)	2007-11-09	2015-02-10	Eisai R&D Management Co., Ltd.	Combination of anti-angiogenic substance and anti-tumor platinum complex
KR101506062B1 (ko) *	2008-01-29	2015-03-25	에자이 알앤드디 매니지먼트 가부시키가이샤	혈관 저해 물질과 탁산의 병용
CN101584696A (zh) *	2008-05-21	2009-11-25	上海艾力斯医药科技有限公司	包含喹唑啉衍生物的组合物及制备方法、用途
WO2010017418A1 (en) *	2008-08-07	2010-02-11	Sepracor Inc.	Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
WO2011017634A2 (en) *	2009-08-07	2011-02-10	Sepracore Inc.	Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
MY162940A (en)	2009-08-19	2017-07-31	Eisai R&D Man Co Ltd	Quinoline derivative-containing pharmaceutical composition
CN102958523B (zh)	2010-06-25	2014-11-19	卫材R&D管理有限公司	使用具有激酶抑制作用的组合的抗肿瘤剂
CN103402519B (zh)	2011-04-18	2015-11-25	卫材R&D管理有限公司	肿瘤治疗剂
JP6038128B2 (ja)	2011-06-03	2016-12-07	エーザイ・アール・アンド・ディー・マネジメント株式会社	レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
AU2013202947B2 (en)	2012-06-13	2016-06-02	Ipsen Biopharm Ltd.	Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en)	2012-06-13	2017-08-01	Ipsen Biopharm Ltd.	Methods for treating pancreatic cancer using combination therapies
KR20150098605A (ko)	2012-12-21	2015-08-28	에자이 알앤드디 매니지먼트 가부시키가이샤	퀴놀린 유도체의 비정질 형태 및 그의 제조방법
NZ714049A (en)	2013-05-14	2020-05-29	Eisai R&D Man Co Ltd	Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
JP6704345B2 (ja)	2014-01-17	2020-06-03	オンコラルファーマエーピーエス	癌治療のためのイリノテカンの固体経口剤形
PT3524595T (pt)	2014-08-28	2022-09-19	Eisai R&D Man Co Ltd	Derivado de quinolina altamente puro e método para produção do mesmo
EP3229802A1 (de) *	2014-12-09	2017-10-18	Ipsen Biopharm Ltd.	Behandlung von brustkrebs mit liposomalem irinotecan
LT3263106T (lt)	2015-02-25	2024-01-10	Eisai R&D Management Co., Ltd.	Chinolino darinių kartumo sumažinimo būdas
KR102662228B1 (ko)	2015-03-04	2024-05-02	머크 샤프 앤드 돔 코포레이션	암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
US11318131B2 (en)	2015-05-18	2022-05-03	Ipsen Biopharm Ltd.	Nanoliposomal irinotecan for use in treating small cell lung cancer
MX373231B (es)	2015-06-16	2020-05-08	Eisai R&D Man Co Ltd	Agente anticancerigeno.
US12220398B2 (en)	2015-08-20	2025-02-11	Eisai R&D Management Co., Ltd.	Tumor therapeutic agent
JP7042739B2 (ja)	2015-08-20	2022-03-28	イプセンバイオファームリミティド	癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法
TW202400181A (zh)	2015-08-21	2024-01-01	英商益普生生物製藥有限公司	使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法
CN110402163A (zh)	2016-11-02	2019-11-01	易普森生物制药有限公司	使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌
US12303505B2 (en)	2017-02-08	2025-05-20	Eisai R&D Management Co., Ltd.	Tumor-treating pharmaceutical composition
RU2019134940A (ru)	2017-05-16	2021-06-16	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Лечение гепатоцеллюлярной карциномы

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1995007276A1 (en) *	1993-09-10	1995-03-16	Eisai Co., Ltd.	Bicyclic heterocyclic sulfonamide and sulfonic ester derivatives
JP3545461B2 (ja) *	1993-09-10	2004-07-21	エーザイ株式会社	二環式ヘテロ環含有スルホンアミド誘導体
JPH09208571A (ja) *	1996-02-02	1997-08-12	Takeda Chem Ind Ltd	アルキリデンシクロヘキサン誘導体
JP2000143635A (ja) *	1998-06-10	2000-05-26	Takeda Chem Ind Ltd	血管新生阻害剤
JP2000247949A (ja) *	1999-02-26	2000-09-12	Eisai Co Ltd	スルホンアミド含有インドール化合物
US6911306B1 (en) *	1999-10-18	2005-06-28	Emory University	TMS1 compositions and methods of use
EP1296714B1 (de) *	2000-06-22	2009-08-26	University Of Iowa Research Foundation	Kombination von CpG und Antikörpern gegen CD19,CD20,CD22 oder CD40 zur Prävention oder Behandlung von Krebs.

2001
- 2001-10-30 TW TW090126893A patent/TWI283575B/zh active
- 2001-10-31 US US10/381,909 patent/US20040002505A1/en not_active Abandoned
- 2001-10-31 KR KR1020037004463A patent/KR100829875B1/ko not_active Expired - Fee Related
- 2001-10-31 EP EP01978983A patent/EP1331005B1/de not_active Expired - Lifetime
- 2001-10-31 JP JP2002538929A patent/JP4167898B2/ja not_active Expired - Fee Related
- 2001-10-31 WO PCT/JP2001/009563 patent/WO2002036117A1/ja not_active Ceased
- 2001-10-31 AU AU1099302A patent/AU1099302A/xx active Pending
- 2001-10-31 NZ NZ524975A patent/NZ524975A/en unknown
- 2001-10-31 CA CA002427617A patent/CA2427617C/en not_active Expired - Fee Related
- 2001-10-31 AU AU2002210993A patent/AU2002210993B2/en not_active Ceased
- 2001-10-31 AT AT01978983T patent/ATE322264T1/de not_active IP Right Cessation
- 2001-10-31 CN CNB018183581A patent/CN1196484C/zh not_active Expired - Fee Related
- 2001-10-31 DE DE60118590T patent/DE60118590T2/de not_active Expired - Lifetime
2003
- 2003-05-08 US US10/431,569 patent/US20030215523A1/en not_active Abandoned
2004
- 2004-05-06 US US10/839,222 patent/US20040224972A1/en not_active Abandoned

Also Published As

Publication number	Publication date
TWI283575B (en)	2007-07-11
NZ524975A (en)	2004-11-26
JP4167898B2 (ja)	2008-10-22
CN1473041A (zh)	2004-02-04
CA2427617A1 (en)	2003-04-29
US20040224972A1 (en)	2004-11-11
US20040002505A1 (en)	2004-01-01
AU1099302A (en)	2002-05-15
EP1331005A4 (de)	2004-12-22
CA2427617C (en)	2009-10-06
EP1331005B1 (de)	2006-04-05
DE60118590T2 (de)	2007-01-18
US20030215523A1 (en)	2003-11-20
WO2002036117A1 (en)	2002-05-10
KR20030046475A (ko)	2003-06-12
AU2002210993B2 (en)	2006-12-07
CN1196484C (zh)	2005-04-13
EP1331005A1 (de)	2003-07-30
KR100829875B1 (ko)	2008-05-16
JPWO2002036117A1 (ja)	2004-03-11
DE60118590D1 (de)	2006-05-18

Legal Events

Date	Code	Title	Description
2006-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE322264T1 (de)	2006-04-15	Medizinische zusammensetzungen als begleittherapie gegen krebs
RU2350605C2 (ru)	2009-03-27	Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ
DE60227794D1 (de)	2008-09-04	Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon
MXPA02011974A (es)	2004-09-06	Derivados de quinazolina sustituidos y su uso como inhibidores.
BR0206955A (pt)	2004-03-09	Ligantes de receptores de canabinóides
SE0102764D0 (sv)	2001-08-17	Compounds
DE60118225D1 (de)	2006-05-11	Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
TNSN06439A1 (fr)	2008-02-22	Derives de 2-carbamide -4-phenylthiazole, leur preparation et leur application en therapeutique
MXPA06001274A (es)	2006-04-11	Compuestos novedosos que poseen actividad inhibitoria contra transporador dependiente de sodio.
DE60330407D1 (de)	2010-01-14	Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
ATE311358T1 (de)	2005-12-15	Immunoregulierende verbindungen, deren derivate und ihre verwendung
BRPI0714885B8 (pt)	2021-05-25	compostos terapêuticos e seu uso
IL174665A0 (en)	2006-08-20	Heterocyclic compounds which act as p-glycoprotein inhibitors and pharmaceutical compositions containing the same
ATE450499T1 (de)	2009-12-15	Durch enzyme spaltbare prodrugs von substituierten stickstoff-lost-derivaten
IL313466B1 (en)	2025-07-01	Inhibiting creb binding protein (cbp)
ATE503746T1 (de)	2011-04-15	Neue imidazolidinderivate
BR0214842A (pt)	2005-01-11	Inibidores de integrase hiv
BRPI0417007A (pt)	2007-01-16	agentes antivirais de diazaindol-dicarbonil-piperazinila
NO20025035D0 (no)	2002-10-18	Oksadiazolderivater som har anticancer-effekter
EE200000472A (et)	2001-12-17	Kasvajavastased toimeained
NO20032261D0 (no)	2003-05-20	Medisinske preparater
FI935800A0 (fi)	1993-12-22	Antidepressiva och mot Parkisons sjukdom verksamma foereningar
CA2535210A1 (en)	2005-02-17	Novel farnesyl protein transferase inhibitors as antitumor agents
ATE320795T1 (de)	2006-04-15	Oberflächenaktive verbindungen und ihre anwendungen
MA30179B1 (fr)	2009-01-02	Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique.